Atorvastatin Versus Simvastatin In The Prevention Of Coronary Heart Disease (CHD) In Patients With Known CHD
NCT ID: NCT00159835
Last Updated: 2015-04-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
8600 participants
INTERVENTIONAL
1999-02-28
2005-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study Of Atorvastatin For The Treatment Of High Cholesterol In Patients At High Risk Of Coronary Heart Disease (CHD)
NCT00644709
Efficacy And Safety Study Of Atorvastatin Versus Simvastatin In Type 2 Diabetic Subjects With Hypercholesterolemia
NCT00141141
A Single-centre Open Label Study to Investigate the Effect of Repeat Doses of SB-649868 on the Pharmacokinetics of Simvastatin and Atorvastatin in Healthy Male Volunteers.
NCT01299597
Dose-ranging Efficacy and Pharmacokinetics Study of Intravenous Atorvastatin in Hypercholesterolemic Patients
NCT03611010
Ezetimibe and Atorvastatin vs. Atorvastatin in Patients Age 65 and Older at High Risk for Coronary Heart Disease (CHD)(0653-112)
NCT00418834
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
atorvastatin
simvastatin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Arhus C, , Denmark
Pfizer Investigational Site
Copenhagen, , Denmark
Pfizer Investigational Site
Elsinore, , Denmark
Pfizer Investigational Site
Esbjerg, , Denmark
Pfizer Investigational Site
Fredericia, , Denmark
Pfizer Investigational Site
Frederiksberg, , Denmark
Pfizer Investigational Site
Frederikssund, , Denmark
Pfizer Investigational Site
Grenå, , Denmark
Pfizer Investigational Site
Hjørring, , Denmark
Pfizer Investigational Site
Holbak, , Denmark
Pfizer Investigational Site
Holstebro, , Denmark
Pfizer Investigational Site
Hvidovre, , Denmark
Pfizer Investigational Site
Kabenhavn S, , Denmark
Pfizer Investigational Site
Kalundborg, , Denmark
Pfizer Investigational Site
København NV, , Denmark
Pfizer Investigational Site
Kobenhavn K, , Denmark
Pfizer Investigational Site
København NV, , Denmark
Pfizer Investigational Site
Køge, , Denmark
Pfizer Investigational Site
Middelfart, , Denmark
Pfizer Investigational Site
Nykøbing Falster, , Denmark
Pfizer Investigational Site
Næstved, , Denmark
Pfizer Investigational Site
Odder, , Denmark
Pfizer Investigational Site
Randers, , Denmark
Pfizer Investigational Site
Roskilde, , Denmark
Pfizer Investigational Site
Silkeborg, , Denmark
Pfizer Investigational Site
Skive, , Denmark
Pfizer Investigational Site
Slagelse, , Denmark
Pfizer Investigational Site
Svendborg, , Denmark
Pfizer Investigational Site
Ekenäs, , Finland
Pfizer Investigational Site
Heinola, , Finland
Pfizer Investigational Site
Helsinki, , Finland
Pfizer Investigational Site
Helsinki, , Finland
Pfizer Investigational Site
Joensuu, , Finland
Pfizer Investigational Site
Jyväskylä, , Finland
Pfizer Investigational Site
Kerava, , Finland
Pfizer Investigational Site
Kuopio, , Finland
Pfizer Investigational Site
Lahti, , Finland
Pfizer Investigational Site
Lappeenranta, , Finland
Pfizer Investigational Site
Lohja, , Finland
Pfizer Investigational Site
Mikkeli, , Finland
Pfizer Investigational Site
Rauma, , Finland
Pfizer Investigational Site
Salo, , Finland
Pfizer Investigational Site
Siaraalamaki, , Finland
Pfizer Investigational Site
Tampere, , Finland
Pfizer Investigational Site
Vantaa, , Finland
Pfizer Investigational Site
Reykjavik, , Iceland
Pfizer Investigational Site
Reykjavik, , Iceland
Pfizer Investigational Site
's-Hertogenbosch, , Netherlands
Pfizer Investigational Site
Alkmaar, , Netherlands
Pfizer Investigational Site
Amsterdam, , Netherlands
Pfizer Investigational Site
Assen, , Netherlands
Pfizer Investigational Site
Breda, , Netherlands
Pfizer Investigational Site
Capelle aan den IJssel, , Netherlands
Pfizer Investigational Site
Delft, , Netherlands
Pfizer Investigational Site
Deventer, , Netherlands
Pfizer Investigational Site
Ede, , Netherlands
Pfizer Investigational Site
Eindhoven, , Netherlands
Pfizer Investigational Site
Enschede, , Netherlands
Pfizer Investigational Site
Goes, , Netherlands
Pfizer Investigational Site
Groningen, , Netherlands
Pfizer Investigational Site
Hoorn, , Netherlands
Pfizer Investigational Site
Nijmegen, , Netherlands
Pfizer Investigational Site
Oss, , Netherlands
Pfizer Investigational Site
Rotterdam, , Netherlands
Pfizer Investigational Site
Tilburg, , Netherlands
Pfizer Investigational Site
Tilurg, , Netherlands
Pfizer Investigational Site
Utrecht, , Netherlands
Pfizer Investigational Site
Weert, , Netherlands
Pfizer Investigational Site
Zwijndrecht, , Netherlands
Pfizer Investigational Site
Zwolle, , Netherlands
Pfizer Investigational Site
Ålesund, , Norway
Pfizer Investigational Site
Ålesund, , Norway
Pfizer Investigational Site
Bergen, , Norway
Pfizer Investigational Site
Bergen, , Norway
Pfizer Investigational Site
Bergen, , Norway
Pfizer Investigational Site
Bergen, , Norway
Pfizer Investigational Site
Bergen, , Norway
Pfizer Investigational Site
Bodø, , Norway
Pfizer Investigational Site
Flekkefjord, , Norway
Pfizer Investigational Site
Førde, , Norway
Pfizer Investigational Site
Hammerfest, , Norway
Pfizer Investigational Site
Haugesund, , Norway
Pfizer Investigational Site
Hobøl, , Norway
Pfizer Investigational Site
Jessheim, , Norway
Pfizer Investigational Site
Karasjok, , Norway
Pfizer Investigational Site
Kongsberg, , Norway
Pfizer Investigational Site
Kongsvinger, , Norway
Pfizer Investigational Site
Kragerø, , Norway
Pfizer Investigational Site
Kristiansand, , Norway
Pfizer Investigational Site
Kristiansund N, , Norway
Pfizer Investigational Site
Larvik, , Norway
Pfizer Investigational Site
Levanger, , Norway
Pfizer Investigational Site
Lillestom, , Norway
Pfizer Investigational Site
Lorenskog, , Norway
Pfizer Investigational Site
Mo i Rana, , Norway
Pfizer Investigational Site
Molde, , Norway
Pfizer Investigational Site
Molde, , Norway
Pfizer Investigational Site
Mosjøen, , Norway
Pfizer Investigational Site
Moss, , Norway
Pfizer Investigational Site
Mysen, , Norway
Pfizer Investigational Site
Nesttun, , Norway
Pfizer Investigational Site
Notodden, , Norway
Pfizer Investigational Site
Odda, , Norway
Pfizer Investigational Site
Oslo, , Norway
Pfizer Investigational Site
Oslo, , Norway
Pfizer Investigational Site
Oslo, , Norway
Pfizer Investigational Site
Oslo, , Norway
Pfizer Investigational Site
Oslo, , Norway
Pfizer Investigational Site
Oslo, , Norway
Pfizer Investigational Site
Oslo, , Norway
Pfizer Investigational Site
Oslo, , Norway
Pfizer Investigational Site
Paradis, , Norway
Pfizer Investigational Site
Porsgrunn, , Norway
Pfizer Investigational Site
Rud, , Norway
Pfizer Investigational Site
Sandvika, , Norway
Pfizer Investigational Site
Skedsmokorset, , Norway
Pfizer Investigational Site
Ski, , Norway
Pfizer Investigational Site
Stavanger, , Norway
Pfizer Investigational Site
Stavanger, , Norway
Pfizer Investigational Site
Stavanger, , Norway
Pfizer Investigational Site
Stavanger, , Norway
Pfizer Investigational Site
Stord, , Norway
Pfizer Investigational Site
Tansberg, , Norway
Pfizer Investigational Site
Trondheim, , Norway
Pfizer Investigational Site
Trondheim, , Norway
Pfizer Investigational Site
Tynset, , Norway
Pfizer Investigational Site
Tønsberg, , Norway
Pfizer Investigational Site
Volda, , Norway
Pfizer Investigational Site
Alingsås, , Sweden
Pfizer Investigational Site
Ängelholm, , Sweden
Pfizer Investigational Site
Bålsta, , Sweden
Pfizer Investigational Site
Borås, , Sweden
Pfizer Investigational Site
Eksjö, , Sweden
Pfizer Investigational Site
Eskilstuna, , Sweden
Pfizer Investigational Site
Fagersta, , Sweden
Pfizer Investigational Site
Falköping, , Sweden
Pfizer Investigational Site
Falun, , Sweden
Pfizer Investigational Site
Finspång, , Sweden
Pfizer Investigational Site
Gateborg, , Sweden
Pfizer Investigational Site
Gävle, , Sweden
Pfizer Investigational Site
Gävle, , Sweden
Pfizer Investigational Site
Gävle, , Sweden
Pfizer Investigational Site
Gävle, , Sweden
Pfizer Investigational Site
Gothenburg, , Sweden
Pfizer Investigational Site
Gothenburg, , Sweden
Pfizer Investigational Site
Grästorp, , Sweden
Pfizer Investigational Site
Halmstad, , Sweden
Pfizer Investigational Site
Hässleholm, , Sweden
Pfizer Investigational Site
Hässleholm, , Sweden
Pfizer Investigational Site
Helsingborg, , Sweden
Pfizer Investigational Site
Helsingborg, , Sweden
Pfizer Investigational Site
Hudiksvall, , Sweden
Pfizer Investigational Site
Jönköping, , Sweden
Pfizer Investigational Site
Kalmar, , Sweden
Pfizer Investigational Site
Karlshamn, , Sweden
Pfizer Investigational Site
Karlskoga, , Sweden
Pfizer Investigational Site
Karlskrona, , Sweden
Pfizer Investigational Site
Karlstad, , Sweden
Pfizer Investigational Site
Katarineholm, , Sweden
Pfizer Investigational Site
Köping, , Sweden
Pfizer Investigational Site
Kristinehamn, , Sweden
Pfizer Investigational Site
Lidköping, , Sweden
Pfizer Investigational Site
Linka Ping, , Sweden
Pfizer Investigational Site
Ljungby, , Sweden
Pfizer Investigational Site
Ludvika, , Sweden
Pfizer Investigational Site
Luleå, , Sweden
Pfizer Investigational Site
Lycksele, , Sweden
Pfizer Investigational Site
Malmo, , Sweden
Pfizer Investigational Site
Malmo, , Sweden
Pfizer Investigational Site
Malmo, , Sweden
Pfizer Investigational Site
Malmo, , Sweden
Pfizer Investigational Site
Mariestad, , Sweden
Pfizer Investigational Site
Motala, , Sweden
Pfizer Investigational Site
Mölndal, , Sweden
Pfizer Investigational Site
Norrköping, , Sweden
Pfizer Investigational Site
Sala, , Sweden
Pfizer Investigational Site
Sandviken, , Sweden
Pfizer Investigational Site
Skellefteå, , Sweden
Pfizer Investigational Site
Skene, , Sweden
Pfizer Investigational Site
Skövde, , Sweden
Pfizer Investigational Site
Södertälje, , Sweden
Pfizer Investigational Site
Stockholm, , Sweden
Pfizer Investigational Site
Stockholm, , Sweden
Pfizer Investigational Site
Stockholm, , Sweden
Pfizer Investigational Site
Stockholm, , Sweden
Pfizer Investigational Site
Stockholm, , Sweden
Pfizer Investigational Site
Stockholm, , Sweden
Pfizer Investigational Site
Strömstad, , Sweden
Pfizer Investigational Site
Uddevalla, , Sweden
Pfizer Investigational Site
Umeå, , Sweden
Pfizer Investigational Site
Varberg, , Sweden
Pfizer Investigational Site
Vänersborg, , Sweden
Pfizer Investigational Site
Västervik, , Sweden
Pfizer Investigational Site
, ,
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M, Tsai J; Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005 Nov 16;294(19):2437-45. doi: 10.1001/jama.294.19.2437.
Tunnicliffe DJ, Palmer SC, Cashmore BA, Saglimbene VM, Krishnasamy R, Lambert K, Johnson DW, Craig JC, Strippoli GF. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev. 2023 Nov 29;11(11):CD007784. doi: 10.1002/14651858.CD007784.pub3.
Ports WC, Fayyad R, DeMicco DA, Laskey R, Wolk R. Effectiveness of Lipid-Lowering Statin Therapy in Patients With and Without Psoriasis. Clin Drug Investig. 2017 Aug;37(8):775-785. doi: 10.1007/s40261-017-0533-0.
Stam-Slob MC, van der Graaf Y, Greving JP, Dorresteijn JA, Visseren FL. Cost-Effectiveness of Intensifying Lipid-Lowering Therapy With Statins Based on Individual Absolute Benefit in Coronary Artery Disease Patients. J Am Heart Assoc. 2017 Feb 18;6(2):e004648. doi: 10.1161/JAHA.116.004648.
Deedwania PC, Pedersen TR, DeMicco DA, Breazna A, Betteridge DJ, Hitman GA, Durrington P, Neil A; TNT, CARDS and IDEAL Steering Committees and Investigators. Differing predictive relationships between baseline LDL-C, systolic blood pressure, and cardiovascular outcomes. Int J Cardiol. 2016 Nov 1;222:548-556. doi: 10.1016/j.ijcard.2016.07.201. Epub 2016 Jul 30.
Stoekenbroek RM, Boekholdt SM, Fayyad R, Laskey R, Tikkanen MJ, Pedersen TR, Hovingh GK; Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group. High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial disease. Heart. 2015 Mar;101(5):356-62. doi: 10.1136/heartjnl-2014-306906. Epub 2015 Jan 16.
Dorresteijn JA, Boekholdt SM, van der Graaf Y, Kastelein JJ, LaRosa JC, Pedersen TR, DeMicco DA, Ridker PM, Cook NR, Visseren FL. High-dose statin therapy in patients with stable coronary artery disease: treating the right patients based on individualized prediction of treatment effect. Circulation. 2013 Jun 25;127(25):2485-93. doi: 10.1161/CIRCULATIONAHA.112.000712. Epub 2013 May 14.
Semb AG, Kvien TK, DeMicco DA, Fayyad R, Wun CC, LaRosa JC, Betteridge J, Pedersen TR, Holme I. Effect of intensive lipid-lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint disease. Arthritis Rheum. 2012 Sep;64(9):2836-46. doi: 10.1002/art.34524.
Hyde CL, Macinnes A, Sanders FA, Thompson JF, Mazzarella RA, Faergeman O, van Wijk DF, Wood L, Lira M, Paciga SA. Genetic association of the CCR5 region with lipid levels in at-risk cardiovascular patients. Circ Cardiovasc Genet. 2010 Apr;3(2):162-8. doi: 10.1161/CIRCGENETICS.109.897793. Epub 2010 Feb 3.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A2581145
Identifier Type: -
Identifier Source: secondary_id
ATV-N-98-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.